- Home
- SNDX
as of 02-10-2026 2:43pm EST
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.8B | IPO Year: | 2016 |
| Target Price: | $80.23 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.58 - $22.73 | Next Earning Date: | 03-02-2026 |
| Revenue: | $111,304,000 | Revenue Growth: | 595.65% |
| Revenue Growth (this year): | 617.4% | Revenue Growth (next year): | 115.70% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -311011000.0 | FCF Growth: | N/A |
AI-Powered SNDX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Syndax Pharmaceuticals Inc. (SNDX)
Chief Financial Officer
Avg Cost/Share
$21.03
Shares
3,410
Total Value
$71,705.48
Owned After
140,429
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$21.03
Shares
17,159
Total Value
$360,819.45
Owned After
491,690
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$20.62
Shares
2,082
Total Value
$42,930.84
Owned After
140,429
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$20.62
Shares
7,412
Total Value
$152,835.44
Owned After
491,690
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Goldan Keith A. | SNDX | Chief Financial Officer | Feb 9, 2026 | Sell | $21.03 | 3,410 | $71,705.48 | 140,429 | |
| Metzger Michael A | SNDX | Chief Executive Officer | Feb 9, 2026 | Sell | $21.03 | 17,159 | $360,819.45 | 491,690 | |
| Goldan Keith A. | SNDX | Chief Financial Officer | Feb 6, 2026 | Sell | $20.62 | 2,082 | $42,930.84 | 140,429 | |
| Metzger Michael A | SNDX | Chief Executive Officer | Feb 6, 2026 | Sell | $20.62 | 7,412 | $152,835.44 | 491,690 |
Compare SNDX vs Leading Stocks
See how SNDX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SNDX Syndax Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.